Actively Recruiting
Safety Evaluation of Restylane Lyft with Lidocaine for Chin Augmentation and Retreatment to Improve Chin Profile
Led by Galderma R&D · Updated on 2026-08-14
100
Participants Needed
8
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
This research is focused on individuals seeking chin augmentation to improve chin profile. It aims to evaluate the safety of retreatment with Restylane Lyft with Lidocaine, a dermal filler device made of sterile hyaluronic acid gel, specifically 3 months after an optional retreatment given 12 months after the last treatment. The study is interventional and sponsored by Galderma R&D, targeting adults aged 22 and older. Participants will receive initial treatment with Restylane Lyft with Lidocaine in the chin region at baseline. They may have an optional touch-up treatment one month after the initial procedure and an optional retreatment 12 months after the last treatment. The retreatment safety will be assessed up to 3 months following this last retreatment. During the study, participants will be monitored for treatment-emergent adverse events related to the device or injection procedure after the optional retreatment period. The main outcome measure is the number of participants experiencing such adverse events from month 12 to month 15. The total participation duration includes initial treatment, optional touch-up, optional retreatment, and safety observation following retreatment.
CONDITIONS
Brief Title
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
Research Team
C
Clinical Project Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here